PE20191105A1 - Inhibidores de moleculas pequenas de lafamilia de quinasas jak - Google Patents
Inhibidores de moleculas pequenas de lafamilia de quinasas jakInfo
- Publication number
- PE20191105A1 PE20191105A1 PE2019001252A PE2019001252A PE20191105A1 PE 20191105 A1 PE20191105 A1 PE 20191105A1 PE 2019001252 A PE2019001252 A PE 2019001252A PE 2019001252 A PE2019001252 A PE 2019001252A PE 20191105 A1 PE20191105 A1 PE 20191105A1
- Authority
- PE
- Peru
- Prior art keywords
- inhibitors
- kinas
- jak
- family
- small molecules
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 150000003384 small molecules Chemical class 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 229940122245 Janus kinase inhibitor Drugs 0.000 abstract 1
- 150000007960 acetonitrile Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Referido a compuestos de 2-((1r,4r)-4-(imidazo[4,5-d]pirrolo[2,3-b]piridina-1(6H)-il)ciclohexil)acetonitrilo, inhibidores de las quinasas Janus (Jack). Ademas, se refiere a composiciones farmaceuticas, metodos de elaboracion, y su uso en el tratamiento de enfermedades, trastornos y condiciones mediadas por Jack.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662435609P | 2016-12-16 | 2016-12-16 | |
| US201762592680P | 2017-11-30 | 2017-11-30 | |
| US201762596607P | 2017-12-08 | 2017-12-08 | |
| PCT/US2017/066744 WO2018112379A1 (en) | 2016-12-16 | 2017-12-15 | Small molecule inhibitors of the jak family of kinases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20191105A1 true PE20191105A1 (es) | 2019-08-23 |
Family
ID=61692222
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2019001252A PE20191105A1 (es) | 2016-12-16 | 2017-12-15 | Inhibidores de moleculas pequenas de lafamilia de quinasas jak |
Country Status (36)
| Country | Link |
|---|---|
| US (5) | US10294226B2 (es) |
| EP (2) | EP4086256A1 (es) |
| JP (2) | JP7291077B2 (es) |
| KR (1) | KR102352462B1 (es) |
| CN (1) | CN110088105B (es) |
| AU (3) | AU2017377069B2 (es) |
| CA (1) | CA3046965A1 (es) |
| CL (1) | CL2019001626A1 (es) |
| CO (1) | CO2019006200A2 (es) |
| CR (1) | CR20190282A (es) |
| CY (1) | CY1125460T1 (es) |
| DK (1) | DK3555097T3 (es) |
| EC (1) | ECSP19042688A (es) |
| ES (1) | ES2922379T3 (es) |
| HR (1) | HRP20220885T1 (es) |
| HU (1) | HUE059274T2 (es) |
| IL (1) | IL267275B (es) |
| JO (1) | JOP20190143B1 (es) |
| LT (1) | LT3555097T (es) |
| MD (1) | MD3555097T2 (es) |
| MX (2) | MX391936B (es) |
| MY (1) | MY196260A (es) |
| NI (1) | NI201900060A (es) |
| NZ (1) | NZ795615A (es) |
| PE (1) | PE20191105A1 (es) |
| PH (1) | PH12019501254A1 (es) |
| PL (1) | PL3555097T3 (es) |
| PT (1) | PT3555097T (es) |
| RS (1) | RS63500B1 (es) |
| SA (1) | SA519402216B1 (es) |
| SI (1) | SI3555097T1 (es) |
| SM (1) | SMT202200326T1 (es) |
| TW (1) | TWI777997B (es) |
| UA (1) | UA125042C2 (es) |
| WO (1) | WO2018112379A1 (es) |
| ZA (1) | ZA201904615B (es) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI3433256T1 (sl) | 2016-10-24 | 2019-11-29 | Astrazeneca Ab | Derivat 6,7,8,9-tetrahidro-3H-pirazolo(4,3-f)izokinolina uporabni v zdravljenju raka |
| JOP20190144A1 (ar) | 2016-12-16 | 2019-06-16 | Janssen Pharmaceutica Nv | إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز |
| UA125042C2 (uk) | 2016-12-16 | 2021-12-29 | Янссен Фармацевтика Нв | Малі молекули-інгібітори кіназ родини jak |
| TWI831738B (zh) | 2016-12-16 | 2024-02-11 | 美商瑞塔醫藥有限責任公司 | 用於抑制ＲＯＲγ及其他用途的嘧啶三環烯酮衍生物 |
| HUE047761T2 (hu) | 2017-01-30 | 2020-05-28 | Astrazeneca Ab | Ösztrogén receptor modulátorok |
| CN112654610B (zh) | 2018-06-15 | 2024-12-24 | 里亚塔医药公司 | 用于抑制IL-17和RORγ的吡唑和咪唑化合物 |
| TW202016110A (zh) * | 2018-06-15 | 2020-05-01 | 比利時商健生藥品公司 | Ｊａｋ激酶家族之小分子抑制劑 |
| WO2019246461A1 (en) | 2018-06-20 | 2019-12-26 | Reata Pharmaceuticals, Inc. | Cysteine-dependent inverse agonists of nuclear receptors ror-gamma/ror-gamma-t and methods of treating diseases or disorders therewith |
| WO2020216936A1 (en) | 2019-04-24 | 2020-10-29 | Janssen Pharmaceutica Nv | Non-clinical liquid formulations of pan-jak inhibitor |
| CN117327083A (zh) * | 2019-06-06 | 2024-01-02 | 杭州高光制药有限公司 | 呋喃并咪唑并吡啶类化合物的合成方法、呋喃并咪唑并吡啶类化合物的晶型及其盐的晶型 |
| CN110483514B (zh) * | 2019-09-16 | 2022-06-14 | 启元生物(杭州)有限公司 | 一种氰基取代的环肼衍生物及其应用 |
| CN114761013A (zh) | 2019-09-27 | 2022-07-15 | 迪斯克医药公司 | 治疗骨髓纤维化和相关病症的方法 |
| KR20220157398A (ko) * | 2020-02-21 | 2022-11-29 | 주하이 유나이티드 라보라토리즈 컴퍼니 리미티드 | Jak 억제제의 결정형 및 그의 적용 |
| JP7719796B2 (ja) | 2020-04-24 | 2025-08-06 | アストラゼネカ・アクチエボラーグ | 医薬製剤 |
| US20210330653A1 (en) | 2020-04-24 | 2021-10-28 | Astrazeneca Ab | Dosage Regimen for the Treatment of Cancer |
| JP2023528223A (ja) | 2020-05-13 | 2023-07-04 | ディスク・メディシン・インコーポレイテッド | 骨髄線維症を処置するための抗ヘモジュベリン（ｈｊｖ）抗体 |
| CN114149428B (zh) * | 2020-09-08 | 2023-06-13 | 中国药科大学 | 吡啶并环类化合物及其制备方法、中间体、组合物和应用 |
| WO2022189496A1 (en) | 2021-03-11 | 2022-09-15 | Janssen Pharmaceutica Nv | Lorpucitinib for use in the treatment of jak mediated disorders |
| CN113292561A (zh) * | 2021-05-22 | 2021-08-24 | 中国药科大学 | 一种二吡咯并吡啶结构的化合物、制备方法和医药用途 |
| CN114432317A (zh) * | 2021-05-31 | 2022-05-06 | 广州嘉越医药科技有限公司 | 吡咯并嘧啶类化合物的用途 |
| CN113861194B (zh) * | 2021-11-10 | 2022-07-05 | 英维沃化工科技(广州)有限公司 | 一种含吡咯并吡啶双酰胺咪唑类化合物及其制备方法和应用 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6080747A (en) | 1999-03-05 | 2000-06-27 | Hughes Institute | JAK-3 inhibitors for treating allergic disorders |
| CZ20013800A3 (cs) | 1999-04-23 | 2002-04-17 | Smithkline Beecham Plc | Polymorf soli 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]-benzyl]thiazolidin-2,4-dionu s kyselinou maleinovou |
| AR033485A1 (es) | 2001-09-25 | 2003-12-26 | Otsuka Pharma Co Ltd | Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma |
| TW200404802A (en) | 2002-05-31 | 2004-04-01 | Schering Corp | Xanthine phosphodiesterase V inhibitor polymorphs |
| GB0319935D0 (en) | 2003-08-26 | 2003-09-24 | Cipla Ltd | Polymorphs |
| US7737279B2 (en) | 2005-05-10 | 2010-06-15 | Bristol-Myers Squibb Company | 1,6-dihydro-1,3,5,6-tetraaza-as-indacene based tricyclic compounds and pharmaceutical compositions comprising same |
| PL1902029T5 (pl) | 2005-07-01 | 2022-08-29 | Wyeth Llc | Krystaliczne postacie 4-[(2,4-dichloro-5-metoksyfenylo)amino]-6-metoksy-7-[3(-4-metylo-1-piperazynylo)propoksy]-3-chinolino-karbonitrylu i sposoby ich wytwarzania |
| EP2251341A1 (en) * | 2005-07-14 | 2010-11-17 | Astellas Pharma Inc. | Heterocyclic Janus kinase 3 inhibitors |
| US8163767B2 (en) | 2005-07-14 | 2012-04-24 | Astellas Pharma Inc. | Heterocyclic Janus Kinase 3 inhibitors |
| EP3031324A3 (en) | 2008-06-10 | 2016-09-07 | AbbVie Inc. | Tricyclic kinase inhibitors |
| EA022488B1 (ru) | 2009-09-03 | 2016-01-29 | Бристол-Майерс Сквибб Кампани | Ингибиторы jak2 и их применение для лечения миелопролиферативных заболеваний и злокачественной опухоли |
| JP2011066747A (ja) * | 2009-09-18 | 2011-03-31 | Panasonic Corp | 弾性波フィルタ |
| CN102711476B (zh) | 2009-12-01 | 2014-12-03 | Abbvie公司 | 新的三环化合物 |
| US8785639B2 (en) | 2009-12-01 | 2014-07-22 | Abbvie Inc. | Substituted dihydropyrazolo[3,4-D]pyrrolo[2,3-B]pyridines and methods of use thereof |
| AR079984A1 (es) * | 2010-01-12 | 2012-03-07 | Hoffmann La Roche | Compuestos heterociclicos triciclicos, composiciones y su uso en el tratamiento de enfermedades mediadas por la inhibicion de jak1 |
| WO2011098673A1 (en) | 2010-02-10 | 2011-08-18 | Genon Biotechnologies Oy | Dual activity kinase domains and uses thereof |
| WO2013007765A1 (en) * | 2011-07-13 | 2013-01-17 | F. Hoffmann-La Roche Ag | Fused tricyclic compounds for use as inhibitors of janus kinases |
| GB201212081D0 (en) | 2012-07-06 | 2012-08-22 | Kalvista Pharmaceuticals Ltd | New polymorph |
| WO2014123167A1 (ja) | 2013-02-08 | 2014-08-14 | 日産化学工業株式会社 | ３環性ピロロピリジン化合物及びｊａｋ阻害剤 |
| EP2924026A1 (en) | 2014-03-28 | 2015-09-30 | Novartis Tiergesundheit AG | Aminosulfonylmethylcyclohexanes as JAK inhibitors |
| CA2944433A1 (en) | 2014-05-14 | 2015-11-19 | Nissan Chemical Industries, Ltd. | Tricyclic compound and jak inhibitor |
| KR20180011272A (ko) | 2015-05-28 | 2018-01-31 | 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 | Jak 키나제 저해제로서 나프티리딘 화합물 |
| EP3371332A4 (en) | 2015-11-04 | 2019-04-03 | Mayo Foundation for Medical Education and Research | METHOD AND MATERIALS FOR TREATING AUTOIMMUNE DISEASES |
| JOP20190053A1 (ar) | 2016-09-23 | 2019-03-21 | Novartis Ag | مركبات أزا إندازول للاستخدام في إصابات الأوتار و/ أو الرباط |
| SI3433256T1 (sl) | 2016-10-24 | 2019-11-29 | Astrazeneca Ab | Derivat 6,7,8,9-tetrahidro-3H-pirazolo(4,3-f)izokinolina uporabni v zdravljenju raka |
| EP3555050A1 (en) | 2016-12-16 | 2019-10-23 | Basf Se | Pesticidal compounds |
| UA125042C2 (uk) | 2016-12-16 | 2021-12-29 | Янссен Фармацевтика Нв | Малі молекули-інгібітори кіназ родини jak |
| CR20190289A (es) | 2016-12-16 | 2019-08-21 | Pfizer | Agonistas receptores de glp-1 y usos de los mismos |
| EP3763717B1 (en) | 2016-12-16 | 2023-03-08 | Eli Lilly And Co. | Pyrido[4,3-d][1,3]oxazin-2-one compounds as mutant idh1 and idh2 inhibitors |
| MX2019006047A (es) | 2016-12-16 | 2019-10-02 | Nestle Sa | Oligosacaridos para generacion de sabor. |
| JOP20190144A1 (ar) | 2016-12-16 | 2019-06-16 | Janssen Pharmaceutica Nv | إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز |
| US10703751B2 (en) | 2017-01-11 | 2020-07-07 | Leo Pharma A/S | Amino-imidazopyridine derivatives as Janus kinase inhibitors and pharmaceutical use thereof |
| HUE047761T2 (hu) | 2017-01-30 | 2020-05-28 | Astrazeneca Ab | Ösztrogén receptor modulátorok |
| SG11201909710XA (en) | 2017-04-21 | 2019-11-28 | Kyn Therapeutics | Indole ahr inhibitors and uses thereof |
| CN106881892B (zh) | 2017-04-27 | 2020-10-16 | 双钱集团（江苏）轮胎有限公司 | 一种轮胎生产用生胎转移系统 |
| TW202016110A (zh) | 2018-06-15 | 2020-05-01 | 比利時商健生藥品公司 | Ｊａｋ激酶家族之小分子抑制劑 |
| WO2020216936A1 (en) | 2019-04-24 | 2020-10-29 | Janssen Pharmaceutica Nv | Non-clinical liquid formulations of pan-jak inhibitor |
-
2017
- 2017-12-15 UA UAA201908086A patent/UA125042C2/uk unknown
- 2017-12-15 TW TW106144095A patent/TWI777997B/zh active
- 2017-12-15 NZ NZ795615A patent/NZ795615A/en unknown
- 2017-12-15 KR KR1020197020121A patent/KR102352462B1/ko active Active
- 2017-12-15 EP EP22178880.5A patent/EP4086256A1/en active Pending
- 2017-12-15 SI SI201731186T patent/SI3555097T1/sl unknown
- 2017-12-15 PL PL17854175.1T patent/PL3555097T3/pl unknown
- 2017-12-15 HR HRP20220885TT patent/HRP20220885T1/hr unknown
- 2017-12-15 MX MX2019007073A patent/MX391936B/es unknown
- 2017-12-15 RS RS20220753A patent/RS63500B1/sr unknown
- 2017-12-15 AU AU2017377069A patent/AU2017377069B2/en active Active
- 2017-12-15 JO JOP/2019/0143A patent/JOP20190143B1/ar active
- 2017-12-15 MD MDE20191212T patent/MD3555097T2/ro unknown
- 2017-12-15 LT LTEPPCT/US2017/066744T patent/LT3555097T/lt unknown
- 2017-12-15 PT PT178541751T patent/PT3555097T/pt unknown
- 2017-12-15 CR CR20190282A patent/CR20190282A/es unknown
- 2017-12-15 EP EP17854175.1A patent/EP3555097B1/en active Active
- 2017-12-15 SM SM20220326T patent/SMT202200326T1/it unknown
- 2017-12-15 CN CN201780077753.4A patent/CN110088105B/zh active Active
- 2017-12-15 MX MX2022004474A patent/MX2022004474A/es unknown
- 2017-12-15 US US15/843,642 patent/US10294226B2/en active Active
- 2017-12-15 PE PE2019001252A patent/PE20191105A1/es unknown
- 2017-12-15 WO PCT/US2017/066744 patent/WO2018112379A1/en not_active Ceased
- 2017-12-15 CA CA3046965A patent/CA3046965A1/en active Pending
- 2017-12-15 JP JP2019531668A patent/JP7291077B2/ja active Active
- 2017-12-15 DK DK17854175.1T patent/DK3555097T3/da active
- 2017-12-15 ES ES17854175T patent/ES2922379T3/es active Active
- 2017-12-15 MY MYPI2019003389A patent/MY196260A/en unknown
- 2017-12-15 HU HUE17854175A patent/HUE059274T2/hu unknown
-
2019
- 2019-01-09 US US16/243,874 patent/US10364246B2/en active Active
- 2019-02-12 US US16/274,142 patent/US11059823B2/en active Active
- 2019-02-13 US US16/275,045 patent/US10487083B2/en active Active
- 2019-06-06 PH PH12019501254A patent/PH12019501254A1/en unknown
- 2019-06-12 CL CL2019001626A patent/CL2019001626A1/es unknown
- 2019-06-12 IL IL267275A patent/IL267275B/en unknown
- 2019-06-13 SA SA519402216A patent/SA519402216B1/ar unknown
- 2019-06-14 EC ECSENADI201942688A patent/ECSP19042688A/es unknown
- 2019-06-14 CO CONC2019/0006200A patent/CO2019006200A2/es unknown
- 2019-06-14 NI NI201900060A patent/NI201900060A/es unknown
- 2019-07-15 ZA ZA2019/04615A patent/ZA201904615B/en unknown
-
2020
- 2020-10-21 AU AU2020257068A patent/AU2020257068A1/en not_active Abandoned
-
2021
- 2021-06-23 US US17/355,472 patent/US12202831B2/en active Active
-
2022
- 2022-06-17 AU AU2022204240A patent/AU2022204240B2/en active Active
- 2022-08-02 CY CY20221100530T patent/CY1125460T1/el unknown
-
2023
- 2023-02-13 JP JP2023019626A patent/JP7493068B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20191105A1 (es) | Inhibidores de moleculas pequenas de lafamilia de quinasas jak | |
| PH12019501355A1 (en) | Small molecule inhibitors of the jak family of kinases | |
| EA201790995A1 (ru) | ЗАМЕЩЕННЫЕ ПИРАЗОЛО[1,5-a]ПИРИМИДИНЫ И ИХ ПРИМЕНЕНИЕ ПРИ ЛЕЧЕНИИ ЗАБОЛЕВАНИЙ | |
| EA201991109A1 (ru) | ПРОИЗВОДНЫЕ [1,2,4]ТРИАЗОЛО[1,5-a]ПИРИМИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PDE2 | |
| NI202000100A (es) | Inhibidores de moléculas pequeñas de la familia de quinasa jak | |
| EA201891897A1 (ru) | 1,5-ДИГИДРО-4H-ПИРАЗОЛО[3,4-d]ПИРИМИДИН-4-ОНЫ И 1,5-ДИГИДРО-4H-ПИРАЗОЛО[4,3-c]ПИРИДИН-4-ОНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ PDE1 | |
| EA201991094A1 (ru) | СОЕДИНЕНИЯ [1,2,4]ТРИАЗОЛО[1,5-a]ПИРИМИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PDE2 | |
| IL246034A0 (en) | History of [1,2,4]triazolo[1,5-a]pyrimidine as protozoan proteasome inhibitors for the treatment of parasitic diseases such as Jericho | |
| EA201990973A1 (ru) | СОЕДИНЕНИЯ [1,2,4]ТРИАЗОЛО[1,5-a]ПИРИМИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PDE2 | |
| TH1901003656A (th) | สารยับยั้งที่มีโมเลกุลขนาดเล็กของวงศ์ jak ของไคเนส | |
| EA201991473A1 (ru) | Имидазопирролопиридин в качестве ингибиторов киназ семейства jak | |
| EA201991472A1 (ru) | Низкомолекулярные ингибиторы киназ семейства jak | |
| EA202190047A1 (ru) | Низкомолекулярные ингибиторы киназ семейства jak | |
| AR114969A1 (es) | Inhibidores de moléculas pequeñas de la familia de quinasas jak |